Cargando…

mRNA therapeutics in cancer immunotherapy

Synthetic mRNA provides a template for the synthesis of any given protein, protein fragment or peptide and lends itself to a broad range of pharmaceutical applications, including different modalities of cancer immunotherapy. With the ease of rapid, large scale Good Manufacturing Practice-grade mRNA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beck, Jan D., Reidenbach, Daniel, Salomon, Nadja, Sahin, Ugur, Türeci, Özlem, Vormehr, Mathias, Kranz, Lena M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047518/ https://www.ncbi.nlm.nih.gov/pubmed/33858437 http://dx.doi.org/10.1186/s12943-021-01348-0

Ejemplares similares

Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination
por: Vormehr, Mathias, et al.
Publicado: (2015)

A liposomal RNA vaccine inducing neoantigen-specific CD4(+) T cells augments the antitumor activity of local radiotherapy in mice
por: Salomon, Nadja, et al.
Publicado: (2020)

CIMT 2018: Pushing frontiers in cancer immunotherapy — Report on the 16(th) Annual Meeting of the Association for Cancer Immunotherapy
por: Beck, Jan, et al.
Publicado: (2018)

CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy
por: Kranz, Lena M., et al.
Publicado: (2017)

Dexamethasone premedication suppresses vaccine-induced immune responses against cancer
por: Vormehr, Mathias, et al.
Publicado: (2020)

Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity
por: Omokoko, Tana A., et al.
Publicado: (2016)

Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16(+) cancer
por: Salomon, Nadja, et al.
Publicado: (2021)

HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory
por: Grunwitz, Christian, et al.
Publicado: (2019)

CIMT 2019: report on the 17th Annual Meeting of the Association for Cancer Immunotherapy
por: Beck, Jan David, et al.
Publicado: (2019)

Polysarcosine-Functionalized mRNA Lipid Nanoparticles Tailored for Immunotherapy
por: Wilhelmy, Christoph, et al.
Publicado: (2023)

CIMT 2014: Next waves in cancer immunotherapy - Report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany
por: Diken, Mustafa, et al.
Publicado: (2014)

CIMT 2016: Mechanisms of efficacy in cancer immunotherapy — Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10–12 2016, Mainz, Germany
por: Kranz, Lena M., et al.
Publicado: (2016)

Racing for a SARS‐CoV‐2 vaccine
por: Türeci, Özlem, et al.
Publicado: (2021)

Targeting the tumor vasculature with engineered cystine-knot miniproteins
por: Lui, Bonny Gaby, et al.
Publicado: (2020)

Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody
por: Bähr-Mahmud, Hayat, et al.
Publicado: (2023)

A TCR-like CAR Promotes Sensitive Antigen Recognition and Controlled T-cell Expansion Upon mRNA Vaccination
por: Birtel, Matthias, et al.
Publicado: (2022)

Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery
por: Han, Geonhee, et al.
Publicado: (2023)

mRNA vaccine for cancer immunotherapy
por: Miao, Lei, et al.
Publicado: (2021)

mRNA vaccines for cancer immunotherapy
por: Vishweshwaraiah, Yashavantha L., et al.
Publicado: (2022)

mRNA delivery in cancer immunotherapy
por: Zhong, Yichen, et al.
Publicado: (2023)

Selective activation of tumor growth-promoting Ca(2+ )channel MS4A12 in colon cancer by caudal type homeobox transcription factor CDX2
por: Koslowski, Michael, et al.
Publicado: (2009)

CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy
por: Kranz, Lena M, et al.
Publicado: (2015)

Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies
por: Omokoko, Tana, et al.
Publicado: (2015)

Targeting the tumor mutanome for personalized vaccination therapy
por: Kreiter, Sebastian, et al.
Publicado: (2012)

Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6
por: Stadler, Christiane R., et al.
Publicado: (2015)

mRNA as a Therapeutics: Understanding mRNA Vaccines
por: Oğuz, Ferdi, et al.
Publicado: (2022)

An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation
por: Muik, Alexander, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera
por: Muik, Alexander, et al.
Publicado: (2022)

Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy
por: Duan, Li-Juan, et al.
Publicado: (2022)

Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer
por: Lordick, Florian, et al.
Publicado: (2023)

mRNA as novel technology for passive immunotherapy
por: Schlake, Thomas, et al.
Publicado: (2018)

NCOA3 is a selective co-activator of estrogen receptor α-mediated transactivation of PLAC1 in MCF-7 breast cancer cells
por: Wagner, Meike, et al.
Publicado: (2013)

Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial
por: Thomas, Stephen J., et al.
Publicado: (2022)

Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy
por: Guevara, Maria L., et al.
Publicado: (2020)

mRNA in cancer immunotherapy: beyond a source of antigen
por: Van Hoecke, Lien, et al.
Publicado: (2021)

Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy
por: Wang, Hong-Li, et al.
Publicado: (2022)

mRNA—From COVID-19 Treatment to Cancer Immunotherapy
por: Krause, Werner
Publicado: (2023)

Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA
por: Asrani, Kirtika H., et al.
Publicado: (2018)

Advancements in mRNA Encoded Antibodies for Passive Immunotherapy
por: Deal, Cailin E., et al.
Publicado: (2021)

CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer
por: Paret, Claudia, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_al194au6reld2jtcumbhr2ujje